Core Alternative Capital’s Pfizer PFE Stock Holding History

Core Alternative Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$315K	Buy	13,063 +1,450	+12%	+$37.9K	0.09%	99
2026 Q1	$326K	Buy	11,613 +1,300	+13%	+$34.6K	0.1%	90
2025 Q4	$257K	Buy	10,313 +5,950	+136%	+$150K	0.07%	99
2025 Q3	$111K	Hold	4,363	–	–	0.03%	96
2025 Q2	$106K	Hold	4,363	–	–	0.03%	99
2025 Q1	$111K	Sell	4,363 -2,635	-38%	-$69K	0.03%	107
2024 Q4	$186K	Sell	6,998 -950	-12%	-$25.8K	0.04%	106
2024 Q3	$230K	Buy	7,948 +500	+7%	+$14.6K	0.04%	103
2024 Q2	$208K	Hold	7,448	–	–	0.04%	102
2024 Q1	$207K	Sell	7,448 -3,068	-29%	-$85.1K	0.04%	106
2023 Q4	$303K	Buy	10,516 +1,141	+12%	+$34.5K	0.05%	103
2023 Q3	$311K	Buy	9,375 +13	+0.1%	+$460	0.05%	105
2023 Q2	$343K	Sell	9,362 -1,021	-10%	-$39.7K	0.05%	82
2023 Q1	$424K	Buy	10,383 +7,931	+323%	+$343K	0.06%	74
2022 Q4	$126K	Sell	2,452 -181	-7%	-$8.68K	0.02%	110
2022 Q3	$115K	Buy	2,633 +157	+6%	+$7.63K	0.02%	106
2022 Q2	$130K	Buy	2,476 +379	+18%	+$19.3K	0.03%	110
2022 Q1	$109K	Buy	2,097 +1,298	+162%	+$67.3K	0.03%	112
2021 Q4	$47K	Buy	799 +90	+13%	+$4.46K	0.01%	121
2021 Q3	$30K	Buy	+709	New	+$31.4K	0.01%	81

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Core Alternative Capital's PFE Position: Q2 2026 in Review

Core Alternative Capital increased its Pfizer (PFE) stake by 12% in Q2 2026, buying an estimated $37.9K and bringing the position to 13,063 shares worth $315K. The position accounts for 0.09% of the portfolio, ranked #99.

Core Alternative Capital first reported a position in PFE in Q3 2021 and has held it in 20 quarters since. The position peaked at $424K in Q1 2023. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Core Alternative Capital held 13,063 shares of Pfizer worth $315K as of Q2 2026.
Core Alternative Capital bought 1,450 Pfizer shares in Q2 2026, an estimated $37.9K.
Pfizer made up 0.09% of Core Alternative Capital's portfolio in Q2 2026, its #99 holding.
Core Alternative Capital first reported a position in Pfizer in Q3 2021 and has held it in 20 quarters since.
Core Alternative Capital's Pfizer position peaked at $424K in Q1 2023.
2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Core Alternative Capital's 13F filing for Q2 2026, filed 14 Aug 2026.